Skip to main content

Use of Valsartan, Angiotensin II Receptor Blockers (ARB), and Angiotensin-Converting Enzyme (ACE) Inhibitors

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    angiotensin II receptor blocker (ARB)
    angiotensin-converting enzyme (ACE) inhibitor
    azilsartan medoxomil
    candesartan
    eprosartan
    irbesartan
    losartan
    olmesartan
    telmisartan
    valsartan
    Description

    This analysis estimates the rates of valsartan (contaminated and uncontaminated with N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA)), angiotensin II receptor blocker (ARB), and angiotensin-converting enzyme (ACE) inhibitor use in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed on October 30, 2018.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - June 30, 2018
    Analysis Type
    Descriptive
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)